You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The company said it will sell off the businesses in order to focus on in vitro diagnostic product development and its diagnostic reagent units.
Rosetta acquired PersonalizeDx and its range of molecular diagnostic offerings in early 2015 for $2 million in cash plus stock.
Hologic's CEO said in December that the blood screening business was a drag on the company's growth.
The company said the divestiture to Varian Medical Systems would allow it to concentrate on investing in high-growth parts of its business.
Hologic CEO Steve MacMillan said that the deal is so compelling that the firm needed to do it now.
The company said it earned approximately $128 million in revenue in 2015, and accessioned 42,000 total commercial diagnostic test samples.
The moves are part of an organizational restructuring designed to increase the company's focus on its core women's health business and reduce operating costs.
Transgenomic has completed its divestment of its Genetic Assays and Platforms unit to Adstec
PDI also said that it would assume the name of its subsidiary, Interpace Diagnostics, to better reflect its focus on its molecular diagnostic operations.
The company sold the technology and assets to Edge BioSystems as part of an ongoing effort to divest legacy non-core businesses and product lines.
The US Food and Drug Administration is to announce stricter standards for emergency authorizations of SARS-CoV-2 vaccines, reports the Washington Post.
The Associated Press reports Johnson & Johnson is starting a late-stage clinical trial of its candidate SARS-CoV-2 vaccine.
Bloomberg reports the budget of Operation Warp Speed is actually $18 billion, higher than the number typically cited.
In Genome Research this week: genomic analysis reveals role of super-spreaders in SARS-CoV-2, epigenetic drivers of cancer, and more.